Literature DB >> 25891096

Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results.

Christine Bergeron1, Hans Ikenberg2, Mario Sideri3, Karin Denton4, Johannes Bogers5, Dietmar Schmidt6, Francisco Alameda7, Thomas Keller8, Susanne Rehm9, Ruediger Ridder9,10.   

Abstract

BACKGROUND: Testing for the presence of the human papillomavirus (HPV) is widely accepted for triaging Papanicolaou cytology results categorized as atypical squamous cells of undetermined significance (ASC-US). In contrast, HPV testing has limited use in triaging cytological low-grade squamous intraepithelial lesions (LSILs) due to prevalence rates of typically >80%. In the current study, the authors assessed the diagnostic performance of p16/Ki-67 dual-stained cytology in triaging ASC-US and LSIL cases within the prospective, multicentric Primary ASC-US LSIL Marker Study (PALMS).
METHODS: A total of 575 ASC-US cases and 529 LSIL cases from a cohort of 27,349 women who were prospectively enrolled into the PALMS study in 5 European countries were tested with p16/Ki-67 dual-stained cytology and Hybrid Capture 2 (HC2) HPV testing. Colposcopy-guided biopsy results of cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) were used as clinical endpoints.
RESULTS: p16/Ki-67 dual-stained cytology demonstrated comparable (ASC-US: 94.4% for dual-stained cytology vs 100% for HC2 testing; P = .317) or lower (LSIL: 85.7% for dual-stained cytology vs 98.4% for HC2 testing; P = .005) sensitivity for CIN2+, but higher levels of specificity compared with HC2 HPV testing in both ASC-US (78.7% vs 60.4%; P<.001) and LSIL (53.3% vs 15.6%; P<.001) cases. Positive predictive values for CIN2+ were substantially higher for dual-stained cytology versus HC2 HPV testing, especially in LSIL, and in ASC-US cases for women aged <30 years.
CONCLUSIONS: The clinical usefulness and efficiency of triaging women with ASC-US or LSIL Papanicolaou cytology results by p16/Ki-67 dual-stained cytology testing has been confirmed in this prospective, pan-European study. The high positive predictive value of dual-stained cytology for the presence of high-grade CIN may help to reduce the number of unnecessary colposcopy referrals.
© 2015 American Cancer Society.

Entities:  

Keywords:  CINtec PLUS; Primary ASC-US LSIL Marker Study (PALMS); atypical squamous cells of undetermined significance (ASC-US); cervical cytology; human papillomavirus (HPV); low-grade squamous intraepithelial lesion (LSIL); p16/Ki-67 dual-stained cytology; triage

Mesh:

Substances:

Year:  2015        PMID: 25891096     DOI: 10.1002/cncy.21542

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  26 in total

Review 1.  Cervical cancer stem cells.

Authors:  Tingting Yao; Rongbiao Lu; Yizhen Zhang; Ya Zhang; Chenyang Zhao; Rongchun Lin; Zhongqiu Lin
Journal:  Cell Prolif       Date:  2015-12       Impact factor: 6.831

Review 2.  [Indications for p16/Ki-67 in cervical cytology].

Authors:  P Ziemke; H Griesser
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

3.  Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women.

Authors:  Carolina Areán-Cuns; Maria Mercado-Gutiérrez; Irene Paniello-Alastruey; Fermín Mallor-Giménez; Alicia Córdoba-Iturriagagoitia; Maria Lozano-Escario; Mercedes Santamaria-Martínez
Journal:  Virchows Arch       Date:  2018-08-09       Impact factor: 4.064

Review 4.  Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice?

Authors:  Gaetano Valenti; Salvatore Giovanni Vitale; Alessandro Tropea; Antonio Biondi; Antonio Simone Laganà
Journal:  Updates Surg       Date:  2017-09-16

Review 5.  [Who performs gynecological cytology and how?].

Authors:  D Schmidt; H H Neumann
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

6.  p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old.

Authors:  Laurențiu Pirtea; Cristina Secosan; Madalin Margan; Lavinia Moleriu; Oana Balint; Dorin Grigoras; Ioan Sas; Florin Horhat; Adelina Jianu; Răzvan Ilina
Journal:  Bosn J Basic Med Sci       Date:  2019-11-08       Impact factor: 3.363

7.  The use of biomarkers and HPV genotyping to improve diagnostic accuracy in women with a transformation zone type 3.

Authors:  Kristyn Manley; Amit Patel; Joya Pawade; Susan Glew; Katherine Hunt; Nichole Villeneuve; Pinias Mukonoweshuro; Samantha Thompson; Helen Hoskins; Andres López-Bernal; Andrew Wills
Journal:  Br J Cancer       Date:  2021-10-29       Impact factor: 7.640

Review 8.  False Negative Results in Cervical Cancer Screening-Risks, Reasons and Implications for Clinical Practice and Public Health.

Authors:  Anna Macios; Andrzej Nowakowski
Journal:  Diagnostics (Basel)       Date:  2022-06-20

9.  Significance of Triple Detection of p16/ki-67 Dual-Staining, Liquid-Based Cytology and HR HPV Testing in Screening of Cervical Cancer: A Retrospective Study.

Authors:  Li Yu; Xun Chen; Xubin Liu; Lingyan Fei; Hanyu Ma; Tian Tian; Liantang Wang; Shangwu Chen
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

10.  Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study.

Authors:  Laura Gilbert; Sam Ratnam; Dan Jang; Reza Alaghehbandan; Miranda Schell; Rob Needle; Anne Ecobichon-Morris; Arnav Wadhawan; Dustin Costescu; Laurie Elit; Peter Wang; George Zahariadis; Max Chernesky
Journal:  Cancer Biomark       Date:  2022       Impact factor: 3.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.